

Our Ref: 530/2021
May 2021

Re: Your request made under the Freedom of Information Act 2000

Analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] **15**
- Adalimumab [Humira] **10**
- Adalimumab[Amgevita] **124**
- Adalimumab[Hymiroz] **0**
- Adalimumab[Imraldi] **0**
- Adalimumab[Idacio] **0**
- Apremilast [Otezla] **1**
- Baricitinib [Olumiant] **4**
- Certolizumab [Cimzia] **0**
- Etanercept [Enbrel] **18**
- EtanerceptBiosimilars **110**
- Filgotinib [Jyseleca] **0**
- Golimumab [Simponi] **35**
- Infliximab [Remicade] **4**
- Infliximab Biosimilars **6**
- Ixekizumab [Taltz] **2**
- Rituximab [MabThera] **0**
- Rituximab Biosimilars **386**
- Sarilumab [Kevzara] **1**
- Secukinumab [Cosentyx] **15**
- Tocilizumab [Ro Actemra] **0**
- Tofacitinib [Xeljanz] **0**
- Upadacitinib [Rinvoq] **0**
- Ustekinumab [Stelara] **3**

Thank you for your time.